Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

RHI Magnesita revenue, earnings slip in FY24

(Sharecast News) - Refractory products supplier RHI Magnesita said on Thursday that both revenue and earnings had slipped in FY24 amid "very weak market conditions". RHI Magnesita said revenues had fallen 1% to €3.48bn in FY24, while adjusted underlying earnings were down 5% at €543.0m and reported pre-tax profits slipped from €233.0m to €200.0m. Earnings per share, however, were up 7% at €5.32 each.

The FTSE 250-listed firm sales volumes fell 1% in its base business, and pricing was down 6%. On the other hand, RHI reduced its net debt position by €53.0m to €1.25bn.

Looking forward, RHI Magnesita said the global refractory industry remains "in flux", with "no signs of immediate recovery" in end markets. It stated China's economic transition continues to impact supply chains and pricing dynamics and noted that market reduction in Western economies seemed "structural and possibly permanent".

Chief executive Stefan Borgas said: "RHI Magnesita has delivered another resilient financial performance despite very weak market demand in most markets around the world. At €407.0m, adjusted EBITA was within our guidance range of €400.0m-€410.0m, reflecting the expected strong performance in the fourth quarter.

"We will continue to manage the business conservatively throughout the ongoing downturn in demand whilst delivering on our strategic objectives to generate long-term value."

As of 1010 GMT, RHI Magnesita shares were down 5.33% at 3,555.0p.

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.